Advertisement

Therapeutic Target Attainment of 3-Hour Extended Infusion of Meropenem in Patients With Septic Burns

      Abstract

      Purpose

      The aim of this prospective cohort study was to evaluate the therapeutic target attainment of 3-hour extended infusion of meropenem in patients with septic burns in the early and late periods of septic shock.

      Methods

      Meropenem serum levels were determined by liquid chromatography from blood samples collected within 48 hours (early period) of therapy and 10 to 14 days afterward (late period). Pharmacokinetic properties were investigated by noncompartmental analysis, and the therapeutic target was defined as 100% of the time above the MIC (100%fT> MIC).

      Findings

      Fifteen patients with 90 measured meropenem concentrations were included. Throughout the entire course of antimicrobial therapy, the therapeutic target was attained against gram-negative pathogens with an MIC ≤ 2 mg/L. Pathogens with intermediate susceptibility to meropenem were only covered in the early phase of therapy.

      Implications

      Higher-dose regimens or continuous infusions may be necessary to guarantee antimicrobial coverage of meropenem against less sensitive pathogens in patients with septic burns.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Greenhalgh DG.
        Sepsis in the burn patient: a different problem than sepsis in the general population.
        Burns Trauma. 2017; 5: 23
        • Pruskowski KA.
        Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Burn Patients.
        Surg Infect (Larchmt). 2021; 22: 77-82
        • Patel BM
        • Paratz J
        • See NC
        • et al.
        Therapeutic drug monitoring of beta-lactam antibiotics in burns patients–a one-year prospective study.
        Ther Drug Monit. 2012; 34: 160-164
        • Doh K
        • Woo H
        • Hur J
        • et al.
        Population pharmacokinetics of meropenem in burn patients.
        J Antimicrob Chemother. 2010; 65: 2428-2435
        • Veiga RP
        • Paiva JA.
        Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
        Crit Care. 2018; 22: 233
        • Singer M
        • Deutschman CS
        • Seymour CW
        • et al.
        The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
        JAMA. 2016; 315: 801-810
        • Cockcroft DW
        • Gault MH.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Santos SRCJ
        • Sanches-Giraud C
        • de Souza FF
        • et al.
        Pharmacokinetic-pharmacodynamic correlation for meropenem applied to a burn child using a bioanalytical liquid chromatographic method.
        Braz J Pharma Sci. 2011; 3: 4-12
      1. MERREM intravenous injection. Package insert. AstraZeneca Pharmaceuticals LP (per FDA), 1996. Accessed January 25, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s037lbl.pdf

        • Jaruratanasirikul S
        • Sriwiriyajan S.
        Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
        J Antimicrob Chemother. 2003; 52: 518-521
      2. Clinical & Laboratory Standards Institute: CLSI Guidelines. Clinical & Laboratory Standards Institute. Accessed July 19, 2021. https://clsi.org/.

        • Church D
        • Elsayed S
        • Reid O
        • Winston B
        • Lindsay R.
        Burn Wound Infections.
        Clin Microbiol Rev. 2006; 19: 403-434
        • Sime FB
        • Roberts MS
        • Peake SL
        • Lipman J
        • Roberts JA.
        Does Beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? a systematic review.
        Ann Intensive Care. 2012; 2: 35
        • Abdul-Aziz MH
        • Lipman J
        • Mouton JW
        • Hope WW
        • Roberts JA.
        Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.
        Semin Respir Crit Care Med. 2015; 36: 136-153
        • Keen EF
        • Robinson BJ
        • Hospenthal DR
        • et al.
        Incidence and bacteriology of burn infections at a military burn center.
        Burns. 2010; 36: 461-468
        • Corcione S
        • D'Avolio A
        • Loia RC
        • et al.
        Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: are we getting close to the right treatment?.
        J Glob Antimicrob Resist. 2020; 20: 22-27
        • Rezaei E
        • Safari H
        • Naderinasab M
        • Aliakbarian H.
        Common pathogens in burn wound and changes in their drug sensitivity.
        Burns. 2011; 37: 805-807
        • Ramon-Lopez A
        • Allen JM
        • Thomson AH
        • et al.
        Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
        J Antimicrob Chemother. 2015; 70: 882-890